Schrödinger (various platforms)

by Schrödinger  · Based in United States → — Physics-based computational platforms for drug discovery and materials science.
Hematology Infectious Disease Oncology
Website
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

Schrödinger is a physics-based computational platform designed to accelerate drug discovery and development through advanced molecular modeling, simulation, and machine learning.

The suite is built for translational researchers, computational chemists, structural biologists, and biopharmaceutical teams working in preclinical drug discovery and translational medicine. It is utilized across biotechnology firms, pharmaceutical companies, and academic research institutions to identify and optimize therapeutic candidates.

In a research and development workflow, Schrödinger integrates into the early-stage pipeline by bridging the gap between experimental and virtual data. It enables teams to transition from target identification to lead optimization before initiating physical synthesis and laboratory assays. The platform supports collaborative decision-making by centralizing project data, allowing cross-functional teams to share validated models and track compound progression in real time.

Notable capabilities include:

  • Maestro: A unified graphical user interface for molecular visualization, modeling, and analysis.
  • Glide: High-accuracy ligand-receptor docking to predict binding modes and screen virtual compound libraries.
  • FEP+ (Free Energy Perturbation): Physics-based calculations that predict ligand binding affinity with high precision.
  • LiveDesign: A cloud-native, collaborative enterprise informatics platform that centralizes experimental and in silico data for real-time team design cycles.
  • BioLuminate: Specialized tools for modeling and optimizing biologics, antibodies, and macromolecular complexes.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Physics-based simulation
  • Machine learning platforms
  • Protein-ligand interaction prediction
  • Molecular dynamics (Desmond)
  • Free energy perturbation (FEP+)
  • Ligand-receptor docking (Glide)
  • Quantum mechanics (Jaguar)
  • Workflow automation (Bunsen)
  • Conformational search (ConfGen)
  • Force field optimization (Force Field Builder)

Use Cases

  • Small molecule drug discovery
  • Biologics drug discovery
  • Materials design and optimization
  • Structure prediction & target enablement
  • Hit-to-lead & lead optimization
  • Drug formulation

What Physicians Need to Know

Molecule Screening Capability
Schru00f6dinger offers robust molecule screening capabilities, including ultra-large scale virtual screening of billions of compounds using physics-based methods and machine learning. Their Virtual Screening Web Service allows for rapid identification of novel hits, and their Shape Screening workflow efficiently screens ultra-large purchasable or synthesizable compound libraries based on ligand shape overlap. The Maestro platform, a cornerstone of their AI-driven drug discovery, utilizes physics-based computational methods and advanced machine learning to predict molecular behavior and interactions, enabling efficient identification of drug candidates. They can screen libraries of over 8 billion molecules, significantly reducing the number of molecules that need to be synthesized and tested in the lab.
Target Identification
Schru00f6dinger's platform aids in identifying druggable targets by using structure-based techniques for target tractability assessment, hit discovery, and ligand binding optimization. They offer solutions to generate design-ready structures from various starting points, including high-resolution X-ray and cryo-EM structures, as well as homology models and AlphaFold structures. Their tools help assess protein binding sites and identify protein-ligand complexes suitable for structure-based drug design. Schru00f6dinger also leverages AI to analyze vast biological datasets, enhancing research capabilities and uncovering breakthrough treatments.
Genomic Data Integration
Schru00f6dinger's platform can harness genomic data to create homology models of pharmaceutically relevant targets and integrate computational chemistry with human genetics data to enhance drug discovery.
Collaboration Features
Schru00f6dinger's LiveDesign platform is a collaborative, cloud-based informatics and analysis environment that enables teams to design, analyze, and share molecular data in real-time. It facilitates data aggregation, model deployment, and team collaboration, allowing for crowdsourcing ideas and interactive refinement of design strategies. They also engage in strategic partnerships and collaborations with pharmaceutical and biotechnology companies, sharing expertise, resources, and costs to accelerate discoveries.
Publication Support
Schru00f6dinger encourages the publication of research findings in peer-reviewed journals and provides resources such as tutorials, webinars, and white papers to support scientific endeavors.
Physician Tip

Schru00f6dinger's advanced computational platform, powered by physics-based simulations and AI/machine learning, can significantly accelerate early-stage drug discovery by rapidly screening billions of molecules and identifying promising candidates. This can lead to a faster path to clinical trials and potentially life-saving medications. Physicians involved in research or drug development should be aware of the platform's capabilities in target identification and lead optimization, as it can help in understanding molecular interactions and predicting drug properties with high accuracy. The collaborative features of platforms like LiveDesign can also streamline communication and data sharing in multidisciplinary research teams.

Schru00f6dinger's platform integrates with various technologies and partners to enhance its capabilities. This includes collaborations with Thermo Fisher Scientific to expand structure-based drug discovery using cryo-EM technology, and partnerships with leading pharmaceutical companies like Bristol Myers Squibb, Takeda, and Sanofi. The platform also leverages Google Cloud for high-performance computing, enabling rapid and efficient processing of massive datasets. Additionally, Schru00f6dinger's LiveDesign platform integrates AI-driven drug discovery workflows, such as those from Eli Lilly's TuneLab, and supports flexible development and exploration of emerging AI/ML technologies through an agnostic API framework. Computer-aided drug discovery software providers are integrating NVIDIA BioNeMo Agent Toolkit capabilities into scientific applications used across discovery teams, which can help orchestrate molecular generation, docking, and prediction. Schru00f6dinger also provides prepared compound libraries from vendors like Enamine, Mcule, Molport, WuXi, and Millipore Sigma for virtual screening.

Details

Category Drug Discovery & Research, Pharmacology & Dosing AI
Pricing Contact for pricing — Not publicly available; contact Schrödinger for details.
DeploymentOn-premise, Cloud-based
Compliance
BAA AvailableUnknown AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Not applicable AI-estimated
Integrations
EHR Not specified
Specialties Hematology, Infectious Disease, Oncology

What the Web Says

Schru00f6dinger offers an advanced simulation software platform for scientific research and molecular modeling, widely used in pharmaceutical R&D for drug discovery, materials design, and protein structure analysis. It's praised for its comprehensive toolset, intuitive graphical user interface, and ability to perform various simulations like homology modeling, protein-ligand docking, and molecular dynamics on a single platform. The software is considered a crucial tool for scientists aiming to innovate and solve complex problems in various research domains, enabling them to optimize molecules, reduce trial-and-error experiments, and accelerate the discovery of novel solutions.

Overall: Positive

Strengths

  • Comprehensive platform for molecular modeling and simulation in drug discovery and materials science.
  • Intuitive and user-friendly graphical interface (Maestro GUI).
  • Ability to perform various simulations (homology modeling, protein-ligand docking, MD simulation) on a single platform.
  • Highly reproducible and scientifically considered results.
  • No coding knowledge needed for many functions, making it accessible.
  • Strong customer support and responsive vendor teams.

Limitations

  • Can be costly compared to free open-source alternatives.
  • Some tools may be challenging for point-and-click users.
  • Limited independent review volume on some platforms.
  • Some workflows might require specialist setup, training, or services.
  • Online courses can be pricey, though scholarships may be available.
  • Occasional reports of crashes or lagging with certain modules (e.g., Maestro).

Based on reviews from: G2, Capterra, SoftwareWorld, Slashdot, Reddit, RFP.wiki, MedAI Verdict, Pharma Now

Last updated: 2026-07-05

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Schrödinger (various platforms)

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Schru00f6dinger, Inc. (via Business Wire)
Schru00f6dinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities
Schru00f6dinger, Inc. provided an update on its 2025 progress and announced 2026 strategic priorities, focusing on advancing its physics+AI computational platform and expanding its leadership in computational molecular discovery. The company highlighted expanded collaborations with Lilly and Manas AI, and positive preclinical data for AJ1-11095, a co-founded program.
2026-01
YouTube (Schru00f6dingerInc)
Schru00f6dinger Release 2026-2 | Life Science - New Features
Schru00f6dinger announced the 2026-2 release of its Life Science suite, featuring advancements like the full release of 'Retro' for synthetic pathway planning, 'Predictive Tox' for identifying liabilities, and integrated co-folding into Maestro for generating diverse structural ensembles. The update aims to streamline workflows and accelerate drug discovery.
2026-05
Google Cloud
New Way Now: Schru00f6dinger recodes the rules of drug discovery with Google Cloud
Schru00f6dinger has leveraged Google Cloud to significantly accelerate drug discovery, reducing calculation times from weeks to hours and enabling the screening of billions of molecules. This partnership allows Schru00f6dinger to scale its computational platform horizontally, transforming the drug discovery paradigm through simulation.
2026-02
Schru00f6dinger, Inc. (via Business Wire)
Schru00f6dinger Reports First Quarter 2026 Financial Results
Schru00f6dinger reported strong Q1 2026 results with a 12% increase in Annual Contract Value (ACV) and significant growth in drug discovery revenue, despite a planned transition to hosted software licensing. The company also announced the upcoming launch of Bunsen, an agentic AI co-scientist, and highlighted Lilly's acquisition of co-founded Ajax Therapeutics.
2026-05
Investing.com
Schru00f6dinger at KeyBanc Forum: Strategic Shift to Hosted Contracts
Schru00f6dinger presented its strategic direction at the 2026 KeyBanc Capital Markets Healthcare Forum, outlining plans to transition 75% of its software contracts to hosted models within three years and aiming for 10-15% ACV growth in 2026. This shift is driven by customer demand for cloud-based solutions and a more stable revenue profile.
2026-03
Simply Wall St
Schru00f6dinger (SDGR) Maintains Guidance And Expands AI Push, Is It Still Below Fair Value?
Schru00f6dinger reiterated its guidance following shareholder approval of an amendment to its 2022 Equity Incentive Plan, focusing on its hosted software transition and the upcoming AI co-scientist, Bunsen. The company's fair value estimate is currently below its trading price, suggesting potential upside for investors.
2026-06
J Med Chem (Schru00f6dinger Publications)
Discovery of a novel mutant-selective epidermal growth factor receptor inhibitor using an in silico enabled drug discovery platform.
This peer-reviewed article details the discovery of a novel mutant-selective epidermal growth factor receptor inhibitor, highlighting the successful application of an in silico enabled drug discovery platform.
2025-02
Nasdaq
Schru00f6dinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schru00f6dinger, Inc. reported granting restricted stock units to newly hired employees under its 2021 Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). These grants serve as a material inducement for employment.
2026-06

Videos

Product demos, reviews, and walkthroughs for Schrödinger (various platforms).

View all on YouTube

Frequently Asked Questions

Schru00f6dinger's platforms offer a range of computational tools, including molecular modeling, simulations, and machine learning, to help predict drug-target interactions, optimize lead compounds, and design novel molecules. This can significantly reduce the time and cost associated with traditional experimental methods by prioritizing the most promising candidates for synthesis and testing.
Schru00f6dinger's platforms are designed with data security in mind, often offering on-premise or secure cloud deployment options. Users are generally responsible for ensuring their research practices comply with relevant regulatory guidelines (e.g., GLP, GCP) and for managing their intellectual property generated through the use of the software. Specific data handling and IP agreements are typically outlined in licensing terms.
Key alternatives include other commercial software suites like OpenEye Scientific (now Cadence Molecular Sciences) and Dassault Systu00e8mes BIOVIA, as well as open-source tools such as RDKit and GROMACS. Differentiators often lie in the specific algorithms employed, user interface, integration capabilities with other software, and pricing models. Schru00f6dinger is often recognized for its comprehensive, integrated suite of tools.
Schru00f6dinger's pricing typically involves a combination of licensing fees for specific modules or suites, often based on the number of users or computational resources required. They generally offer various licensing models, and academic discounts or special programs for research institutions are commonly available. Specific pricing details usually require direct consultation with their sales team.
While powerful, computational platforms like Schru00f6dinger's are still predictive tools and have inherent limitations, such as the accuracy of force fields, approximations in algorithms, and the completeness of input data. Experimental validation remains absolutely necessary to confirm computational predictions, assess biological activity, toxicity, and pharmacokinetics in vitro and in vivo, and ultimately ensure drug safety and efficacy.

Related Tools

Noodle Biomedical Literature Discovery
Helena Bioinformatics
Drug Discovery & Research
Noodle is a biomedical literature discovery platform that allows researchers to search publications by meaning, inspect paper details, and explore related evidence through citation connections and semantic neighborhoods. It offers a public read-only Model Context Protocol (MCP) interface for AI agents.
Free
Trially AI
Trially AI
Drug Discovery & Research
Trially's HIPAA-compliant AI platform matches, engages, and enrolls patients into trials with high accuracy, built for physicians and research sites.
Trial Library
Trial Library
Drug Discovery & Research
Trial Library's AI-native platform is embedded in community oncology practices to identify eligible patients for oncology clinical trials. It integrates clinical trials into routine care, activating providers, identifying eligible patients, and navigating them through the trial lifecycle across health systems, biopharma, and payers.
Mendel.ai
Mendel.ai
Clinical Decision Support & Reference
Mendel.ai uses Neuro-Symbolic AI to sort patient cohorts from EHRs for clinical trial matching, accelerating research.
Contact for pricing
Haystack Enroll
Haystack Health
Drug Discovery & Research
Haystack Health is a clinical trial platform that utilizes AI and care navigation to connect health plan members and ACO patients with relevant clinical trials, aiming to expand treatment access and improve outcomes.
Custom quote
Dyania Health Clinical Trial Recruitment
Dyania Health
Drug Discovery & Research
Dyania Health's AI-powered software automates patient identification from EHRs for clinical trial recruitment, serving hospitals, health systems, and pharmaceutical companies.

See all Drug Discovery & Research tools →

Suggest an Edit → | Last Verified: 2026-07-03 | First Added: 2026-07-03
AI Tool Finder
AI-powered search. Results may not be comprehensive.